Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nutriband ( (NTRB) ) just unveiled an announcement.
On March 30, 2026, Nutriband Inc. announced it has chosen a commercial worldwide brand name candidate for its lead product, an abuse-deterrent fentanyl transdermal system, developed with branding specialist Brand Institute. The name and labeling are being submitted to regulators and for trademark protection, a key step toward commercialization of what could become the first abuse-deterrent fentanyl patch.
The product uses Nutriband’s AVERSA technology and is initially targeting the U.S. market, where peak annual sales are estimated between $80 million and $200 million, with development also planned for other major global markets. By investing in a distinct, regulator-vetted brand identity designed to reduce medication errors, Nutriband is advancing its late-stage asset and reinforcing its positioning in the pain-management segment focused on curbing opioid misuse.
The most recent analyst rating on (NTRB) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Nutriband stock, see the NTRB Stock Forecast page.
Spark’s Take on NTRB Stock
According to Spark, TipRanks’ AI Analyst, NTRB is a Neutral.
Nutriband’s overall stock score is driven by a strong corporate event with positive market reception, offset by challenging financial performance and valuation issues. The technical analysis provides mixed signals, suggesting cautious optimism. The potential for shareholder value enhancement through recent corporate actions improves the score despite underlying financial weaknesses.
To see Spark’s full report on NTRB stock, click here.
More about Nutriband
Nutriband Inc., listed on Nasdaq, develops prescription transdermal pharmaceutical products, with a primary focus on its AVERSA abuse-deterrent transdermal technology. The company’s lead product under development is an abuse-deterrent fentanyl patch aimed at preventing abuse, diversion, misuse and accidental exposure of opioid and other high-risk drugs.
AVERSA technology can be incorporated into a wide range of transdermal patches to improve the safety profile of drugs with abuse potential while maintaining access for patients in need. The platform is supported by a broad international patent portfolio, with protections granted in major markets including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico and Australia.
Average Trading Volume: 13,813
Technical Sentiment Signal: Sell
Current Market Cap: $45.41M
For a thorough assessment of NTRB stock, go to TipRanks’ Stock Analysis page.